Preservation of beta cell function.
Sperling
Mark A
MA
Children's Hospital of Pittsburgh of UPMC and The University of Pittsburgh School of Medicine Pittsburgh, PA, USA.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D002986:Clinical Trials as Topic; D048909:Diabetes Complications / Q000517:prevention & control*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D004333:Drug Administration Routes; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007167:Immunotherapy / Q000379:methods*; D007328:Insulin / Q000008:administration & dosage / Q000378:metabolism; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D051379:Mice; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007004:Hypoglycemic Agents; D007328:Insulin; D000069283:Rituximab